776 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Tuesday’s Close
BMY Bristol-Myers Squibb Company $61.3 $100.03B Uptrend
Article Searches
Clovis Stalls Mid-Stage Rubraca Study for Bladder Cancer http://www.zacks.com/stock/news/380655/clovis-stalls-mid-stage-rubraca-study-for-bladder-cancer?cid=CS-ZC-FT-380655 Apr 15, 2019 - Clovis Oncology (CLVS) halts mid-stage bladder cancer study evaluating Rubraca monotherapy. It is unlikely to provide meaningful clinical benefit as reviewed by an independent data monitoring committee.
Pharma Stock Roundup: AZN, MRK, GSK Get Regulatory Approvals, Sandoz Inks New Deal http://www.zacks.com/stock/news/379777/pharma-stock-roundup-azn-mrk-gsk-get-regulatory-approvals-sandoz-inks-new-deal?cid=CS-ZC-FT-379777 Apr 12, 2019 - Glaxo (GSK) gets FDA approval for a new HIV medicine, Dovato. AstraZeneca (AZN)/Merck's (MRK) Lynparza gets approval in EU for metastatic breast cancer.
Seattle Genetics' Adcetris Progresses Well Amid Competition http://www.zacks.com/stock/news/379195/seattle-genetics-adcetris-progresses-well-amid-competition?cid=CS-ZC-FT-379195 Apr 11, 2019 - Seattle Genetics (SEGN) focuses on improving sales of its flagship product, Adcetris. The drug's label expansion programs also appear encouraging.
Celgene & Acceleron Submit BLA for Luspatercept to the FDA http://www.zacks.com/stock/news/372710/celgene-acceleron-submit-bla-for-luspatercept-to-the-fda?cid=CS-ZC-FT-372710 Apr 08, 2019 - Celgene (CELG) and partner Acceleron submit BLA for pipeline candidate, luspatercept to the FDA.
Why the Earnings Surprise Streak Could Continue for Bristol-Myers (BMY) http://www.zacks.com/stock/news/372339/why-the-earnings-surprise-streak-could-continue-for-bristol-myers-bmy?cid=CS-ZC-FT-372339 Apr 08, 2019 - Bristol-Myers (BMY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Pharma Stock Roundup: NVS Inks Immunology Deal, PFE, TEVA Get Drug Approvals in EU http://www.zacks.com/stock/news/371503/pharma-stock-roundup-nvs-inks-immunology-deal-pfe-teva-get-drug-approvals-in-eu?cid=CS-ZC-FT-371503 Apr 05, 2019 - Novartis (NVS) announces plans to acquire IFM Tre, a subsidiary of IFM Therapeutics focused on anti-inflammatory drugs. Pfizer (PFE) & Teva's (TEVA) drugs get regulatory approvals in EU.
Clovis Posts Data on Rubraca Study for Pancreatic Cancer http://www.zacks.com/stock/news/370142/clovis-posts-data-on-rubraca-study-for-pancreatic-cancer?cid=CS-ZC-FT-370142 Apr 03, 2019 - Clovis (CLVS) presents interim data from the phase II study on Rubraca for the first-line maintenance treatment of patients with advanced pancreatic cancer.
Celgene Gets Positive CHMP Nod for Revlimid Label Expansion http://www.zacks.com/stock/news/368646/celgene-gets-positive-chmp-nod-for-revlimid-label-expansion?cid=CS-ZC-FT-368646 Apr 01, 2019 - Celgene (CELG) receives positive CHMP opinion for label expansions of IMiD medications - Revlimid and Imnovid.
3 Big Pharma Stocks to Add to Your Portfolio This April http://www.zacks.com/stock/news/368171/3-big-pharma-stocks-to-add-to-your-portfolio-this-april?cid=CS-ZC-FT-368171 Apr 01, 2019 - The large-cap pharma industry is on a strong footing in 2019. Here are three stocks from the space that investors may consider betting on.
Top Research Reports for Phillip Morris, Bristol-Myers & Walgreens Boots http://www.zacks.com/research-daily/367230/top-research-reports-for-phillip-morris-bristol-myers-walgreens-boots?cid=CS-ZC-FT-367230 Mar 29, 2019 - Top Research Reports for Phillip Morris, Bristol-Myers & Walgreens Boots

Pages: 123456789...78

<<<Page 4>